The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

Publications

Lazzeroni M, Kemp P, Fokkens WJ, Reitsma S

Eosinophilic complications during dupilumab therapy for type 2 diseases: a systematic review.

Rhinology. 2025;63(4):386-396

Nakashima D, Mori E, Otori N

A case of recurrent chronic eosinophilic pneumonia after switching from benralizumab to dupilumab.

Respiratory medicine case reports. 2024;47:101968

Kanata K, Shirai T, Ichijo K, Uehara M

Eosinophilic pneumonia developed after dupilumab administration in a patient with atopic dermatitis.

Respirology case reports. 2023;11(8):e01192

Menzella F, Montanari G, Patricelli G, Cavazza A, Galeone C, Ruggiero P, Bagnasco D, Facciolongo N

A case of chronic eosinophilic pneumonia in a patient treated with dupilumab.

Therapeutics and clinical risk management. 2019;15:869-875